ResearchEvaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy
ResearchCISH, a key intracellular checkpoint, in comparison and combination to existing and emerging cancer immune checkpoints
ResearchAge- and sex-based differences in the genomic profiles of patients with gastrointestinal and pancreatic neuroendocrine neoplasms
ResearchSTAR (stroma-tumor AI risk) assessment: association of AI-derived tumor-stroma proportion with patient survival provides added prognostic value beyond KELIM in epithelial ovarian cancer
ResearchClinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer
ResearchInvestigational CRISPR-Cas9-edited T cells for metastatic colorectal cancer treatment: Clinical insights for future development
ResearchCXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer
ResearchThe genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs) including small-cell lung cancer (SCLC)
ResearchGenomic and transcriptomic differences between neuroendocrine neoplasms and carcinomas with human papillomavirus (HPV)
ResearchImmunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors
ResearchBroader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy
ResearchSex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes
ResearchValidation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
ResearchUncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy
ResearchMolecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma